Nanobiotix Shares Surge Forward Following FDA Green Light on NANORAY-312
The stock of the French biotech firm rallies during Tuesday's session, following the announcement of the Phase 3 NANORAY-312 trial. The share price is hovering near its 50-day moving average in a positively trending Parisian market.
FDA Approval Boosts Stock
Nanobiotix shares are up 2.41% at €27.16 during the session, after a 4.32% drop the previous day. The rebound follows the FDA's acceptance of an amendment to the protocol of the global Phase 3 NANORAY-312 study, targeting head and neck cancer. The amendment, submitted by Johnson & Johnson, the global sponsor of the candidate JNJ-1900 (NBTXR3), modifies the analysis device and could, according to the company, accelerate the development schedule of the program. Over one year, the stock maintains a performance of 792%, driven by successive clinical advances on the biotech's nanoparticle platform.
Stock Price Caught Between MM50 and €28.95 Resistance
At €27.16, the stock is just above its 50-day moving average (€26.97) and remains about 6.6% from its identified resistance at €28.95. The RSI at 47 indicates a balance between buyers and sellers, following a 4.23% decline over seven days. The price is positioned in the middle of the Bollinger Bands, without any extreme signals. The Parisian context remains favorable, with the CAC 40 up 0.64% at 8,026.91 points. The biotech, with a beta of 0.25 indicating a low correlation with the index, primarily moves at the pace of its own clinical catalysts. The next technical marker is at the €28.95 resistance, which was approached in late April without being breached.
